Bharat Biotech Covaxin demonstrates 78% efficacy in Phase-3 interim analysis

Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 percent against mild, moderate, and severe COVID-19 disease, the company said.

from Moneycontrol Business News https://ift.tt/2QMN6t9